Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates
ASCO 2026
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517).
The ASCO Post Staff
Thomas A. Jandl, MD, PhD, of Stony Brook University Hospital, discusses data from part 1B of the OLYMPIA-3 trial, which showed that among patients with diffuse large B-cell lymphoma (DLBCL), the safety profile of the first-line combination of odronextamab and CHOP chemotherapy was generally manageable and preliminary efficacy was encouraging, with no meaningful differences between regimens. Additionally, combination with odronextamab did not impact the delivery of CHOP (Abstract 7009).
The ASCO Post Staff
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanubrutinib for patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as the doublet’s effect on measurable residual disease (Abstract 7043). He also discusses the phase III BGB-11417-304/CELESTIAL-TNCLL-2 trial; this ongoing study is evaluating sonrotoclax plus zanubrutinib vs venetoclax and acalabrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) (Abstract TPS7099).
The ASCO Post Staff
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).
Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515).
The ASCO Post Staff
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).
